BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in Mylan NV (NASDAQ:MYL) by 22.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,856 shares of the company’s stock after purchasing an additional 23,520 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Mylan were worth $3,558,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of MYL. First Hawaiian Bank increased its position in shares of Mylan by 560.4% during the fourth quarter. First Hawaiian Bank now owns 2,886 shares of the company’s stock worth $79,000 after acquiring an additional 2,449 shares during the period. NuWave Investment Management LLC increased its position in shares of Mylan by 18.1% during the fourth quarter. NuWave Investment Management LLC now owns 3,136 shares of the company’s stock worth $86,000 after acquiring an additional 480 shares during the period. FNY Investment Advisers LLC increased its position in shares of Mylan by 42.8% during the fourth quarter. FNY Investment Advisers LLC now owns 3,300 shares of the company’s stock worth $90,000 after acquiring an additional 989 shares during the period. Quantamental Technologies LLC purchased a new position in shares of Mylan during the fourth quarter worth approximately $100,000. Finally, Huntington National Bank increased its position in shares of Mylan by 200.4% during the fourth quarter. Huntington National Bank now owns 3,860 shares of the company’s stock worth $106,000 after acquiring an additional 2,575 shares during the period. 83.01% of the stock is currently owned by institutional investors.
MYL has been the topic of a number of research reports. Argus raised shares of Mylan from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Thursday, November 15th. Cantor Fitzgerald reiterated a “hold” rating and set a $41.00 price objective on shares of Mylan in a research note on Tuesday, November 20th. ValuEngine downgraded shares of Mylan from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 21st. Zacks Investment Research upgraded shares of Mylan from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Tuesday, January 8th. Finally, UBS Group downgraded shares of Mylan from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $54.00 to $32.00 in a research note on Wednesday, January 23rd. Three analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. Mylan currently has a consensus rating of “Buy” and an average target price of $40.72.
NASDAQ MYL opened at $28.00 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 0.83 and a current ratio of 1.39. Mylan NV has a 52-week low of $26.00 and a 52-week high of $42.50. The company has a market cap of $14.24 billion, a PE ratio of 6.11, a price-to-earnings-growth ratio of 1.15 and a beta of 1.47.
Mylan (NASDAQ:MYL) last released its quarterly earnings data on Tuesday, February 26th. The company reported $1.30 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.06). The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.10 billion. Mylan had a net margin of 3.08% and a return on equity of 19.06%. Mylan’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.43 earnings per share. On average, equities analysts predict that Mylan NV will post 4.38 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4222654/mylan-nv-myl-position-increased-by-british-columbia-investment-management-corp.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Recommended Story: Cost of Equity For A Business, Investors
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.